Response of Eltrombopag in Immune Thrombocytopenia and Acquired Idiopathic Aplastic Anemia: A Single-center Experience

Overview

Journal Leuk Res Rep

Date 2022 Mar 4

PMID 35242527

Authors

Abdul Muqtadir Abbasi

Mohammad Usman Shaikh

Natasha Ali

Maria Khan

Salman Muhammad Soomar

Affiliations

Soon will be listed here.

Abstract

Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Citing Articles

Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.

Zhang Y, Li J, Li X, Geng Q, Xie Y, Zhang G Syst Rev. 2024; 13(1):101.

PMID: 38576005 PMC: 10993616. DOI: 10.1186/s13643-024-02515-2.

References

Cheng G, Saleh M, Marcher C, Vasey S, Mayer B, Aivado M . Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2010; 377(9763):393-402. DOI: 10.1016/S0140-6736(10)60959-2. View

Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther M . The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16):4190-207. DOI: 10.1182/blood-2010-08-302984. View

Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y . A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012; 10(5):799-806. DOI: 10.1111/j.1538-7836.2012.04695.x. View

Wong R, Saleh M, Khelif A, Salama A, Portella M, Burgess P . Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130(23):2527-2536. DOI: 10.1182/blood-2017-04-748707. View

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

Kuwana M, Okazaki Y, Ikeda Y . Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2008; 7(2):322-9. DOI: 10.1111/j.1538-7836.2008.03161.x. View

Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U . A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow.... Blood. 2011; 117(17):4434-41. DOI: 10.1182/blood-2010-08-304071. View

Townsley D, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O . Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017; 376(16):1540-1550. PMC: 5548296. DOI: 10.1056/NEJMoa1613878. View

Saleh M, Bussel J, Cheng G, Meyer O, Bailey C, Arning M . Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2012; 121(3):537-45. DOI: 10.1182/blood-2012-04-425512. View

10.

Brynes R, Orazi A, Theodore D, Burgess P, Bailey C, Thein M . Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. Am J Hematol. 2015; 90(7):598-601. DOI: 10.1002/ajh.24011. View

11.

Erickson-Miller C, Delorme E, Tian S, Hopson C, Stark K, Giampa L . Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005; 33(1):85-93. DOI: 10.1016/j.exphem.2004.09.006. View

12.

Scheinberg P . Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2018; 2(21):3054-3062. PMC: 6234374. DOI: 10.1182/bloodadvances.2018020248. View

13.

Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D . Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2010; 51(6):842-56. DOI: 10.1177/0091270010375427. View

14.

Kovtonyuk L, Manz M, Takizawa H . Enhanced thrombopoietin but not G-CSF receptor stimulation induces self-renewing hematopoietic stem cell divisions in vivo. Blood. 2016; 127(25):3175-9. DOI: 10.1182/blood-2015-09-669929. View

15.

Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y . Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012; 9(2):77-86. PMC: 3412938. DOI: 10.1016/j.scr.2012.05.001. View

16.

Neunert C, Noroozi N, Norman G, Buchanan G, Goy J, Nazi I . Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2014; 13(3):457-64. PMC: 4991942. DOI: 10.1111/jth.12813. View

17.

Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B . Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017; 16(6):620-632. DOI: 10.1016/j.autrev.2017.04.012. View

18.

Desmond R, Townsley D, Dumitriu B, Olnes M, Scheinberg P, Bevans M . Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2013; 123(12):1818-25. PMC: 3962161. DOI: 10.1182/blood-2013-10-534743. View

19.

Liu X, Hou M, Li J, Jin J, Huang M, Yu Z . Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. Platelets. 2020; 33(1):82-88. DOI: 10.1080/09537104.2020.1847267. View

20.

Lambert M, Gernsheimer T . Clinical updates in adult immune thrombocytopenia. Blood. 2017; 129(21):2829-2835. PMC: 5813736. DOI: 10.1182/blood-2017-03-754119. View